Skip to main content
Back
PFE logo

Pfizer Inc.

Data quality: 100%
PFE
NYSE Healthcare Drug Manufacturers - General
$26.78
▼ $0.19 (-0.70%)
Mkt Cap: 152.28B
Day Range
$26.64 $27.19
52-Week Range
$20.92 $27.94
Volume
29,576,037
50D / 200D Avg
$26.63 / $25.30
Prev Close
$26.97

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E 19.6 0.4
P/B 1.8 2.9
ROE % 8.9 3.8
Net Margin % 12.4 3.9
Rev Growth 5Y % -6.3 10.0
D/E 0.8 0.2

Analyst Price Target

Hold
$27.50 +2.7%
Low: $24.00 High: $35.00
Forward P/E
9.1
Forward EPS
$2.96
EPS Growth (est.)
+0.0%
Est. Revenue
61 B

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2030 $2.23
$2.15 – $2.31
52 B 6
FY2029 $2.19
$2.11 – $2.27
52 B 6
FY2028 $2.45
$1.61 – $2.91
55 B 8

Key Takeaways

Revenue declined -6.33% annually over 5 years
Generating 9.08B in free cash flow
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 4.68%
Cash machine — converts 116.81% of earnings into free cash flow
Capital efficient — spends only 4.20% of revenue on capex

Growth

Revenue Growth (5Y)
-6.33%
Revenue (1Y)-1.65%
Earnings (1Y)-3.12%
FCF Growth (3Y)37.61%

Quality

Return on Equity
8.90%
ROIC7.52%
Net Margin12.42%
Op. Margin24.67%

Safety

Debt / Equity
0.78
Current Ratio1.16
Interest Coverage5.78

Valuation

P/E Ratio
19.60
P/B Ratio1.76
EV/EBITDA14.16
Dividend Yield0.07%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -1.65% Revenue Growth (3Y) 2.51%
Earnings Growth (1Y) -3.12% Earnings Growth (3Y) 90.86%
Revenue Growth (5Y) -6.33% Earnings Growth (5Y) -23.04%
Profitability
Revenue (TTM) 62.58B Net Income (TTM) 7.77B
ROE 8.90% ROA 3.73%
Gross Margin 70.33% Operating Margin 24.67%
Net Margin 12.42% Free Cash Flow (TTM) 9.08B
ROIC 7.52% FCF Growth (3Y) 37.61%
Safety
Debt / Equity 0.78 Current Ratio 1.16
Interest Coverage 5.78 Dividend Yield 0.07%
Valuation
P/E Ratio 19.60 P/B Ratio 1.76
P/S Ratio 2.43 PEG Ratio -4.31
EV/EBITDA 14.16 Dividend Yield 0.07%
Market Cap 152.28B Enterprise Value 218.55B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 62.58B 63.63B 59.55B 100.33B 81.29B
Net Income 7.77B 8.02B 2.13B 31.37B 22.15B
EPS (Diluted) 1.36 1.41 0.37 5.47 3.88
Gross Profit 44.01B 41.85B 30.34B 62.09B 46.88B
Operating Income 15.44B 16.48B 5.29B 37.55B 20.79B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 208.16B 213.40B 226.50B 197.21B 181.48B
Total Liabilities 121.39B 124.90B 137.21B 101.29B 104.01B
Shareholders' Equity 86.48B 88.20B 89.01B 95.66B 77.20B
Total Debt 67.42B 66.99B 70.85B 34.86B 37.00B
Cash & Equivalents 1.14B 1.04B 2.85B 416.00M 1.94B
Current Assets 42.90B 50.36B 43.33B 51.26B 59.69B
Current Liabilities 36.98B 43.00B 47.79B 42.14B 42.67B